We are live on ! Find out more
FCMI

Foresite Capital Management III Portfolio holdings

AUM $37.9M
1-Year Est. Return 6.87%
This Fund
S&P 500
This Quarter Est. Return
+33.27%
1 Year Est. Return
-6.87%
3 Year Est. Return
+444.07%
5 Year Est. Return
+547.28%
10 Year Est. Return
–
AUM
$134M
AUM Growth
+$21.8M
Cap. Flow
-$1.43M
Cap. Flow %
-1.06%
Top 10 Hldgs %
100%
Holding
12
New
4
Increased
3
Reduced
–
Closed
2

Top Buys

Rank Stock Value
1
VRNA
Verona Pharma
VRNA
+$7.68M
2
XLRN
Acceleron Pharma
XLRN
+$6.63M
3
KYNB
Kyntra Bio
KYNB
+$5.7M
4
ACRS icon
Aclaris Therapeutics
ACRS
+$1.53M
5
NVAX icon
Novavax
NVAX
+$609K

Top Sells

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$19.5M
2
ORIC icon
Oric Pharmaceuticals
ORIC
+$16.8M

Sector Composition

Rank Sector Weight
1 Healthcare 90.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MYOK
1
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$54.4M 40.54%
399,360
– –
NTRA icon
2
Natera
NTRA
$36.7B
$15.1M 11.23%
208,768
– –
XLRN
3
DELISTED
Acceleron Pharma
XLRN
$12.2M 9.1%
108,630
+66,600
+158% +$6.63M
EPZM
4
DELISTED
Epizyme, Inc
EPZM
$11.9M 8.87%
998,278
– –
CBAY
5
DELISTED
Cymabay Therapeutics
CBAY
$11.9M 8.85%
1,641,804
+41,846
+3% +$224K
KYNB
6
Kyntra Bio
KYNB
$29M
$7.09M 5.28%
6,900
+5,300
+331% +$5.7M
VRNA
7
DELISTED
Verona Pharma
VRNA
$6.93M 5.16%
+1,111,112
New +$7.68M
ACRS icon
8
Aclaris Therapeutics
ACRS
$732M
$1.76M 1.31%
+684,912
New +$1.53M
NVAX icon
9
Novavax
NVAX
$1.2B
$542K 0.4%
+5,000
New +$609K
BPMC
10
DELISTED
Blueprint Medicines
BPMC
– –
-249,598
Closed -$19.5M
ORIC icon
11
Oric Pharmaceuticals
ORIC
$1.22B
– –
-496,893
Closed -$16.8M

Similar funds

PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
KCGDR
Kiron Capital Gestao de Recursos Sao Paulo, Brazil $36.9M AUM 49.85% 1-Year Est. Return
SEM
Spectrum Equity Management San Francisco, California $39.1M AUM 63.69% 1-Year Est. Return
ALFIA
Accel Leaders Fund II Associates Palo Alto, California $36.6M AUM 58.14% 1-Year Est. Return
MCMI
Matrix China Management III Grand Cayman, Cayman Islands $39.3M AUM
LCM
LH Capital Markets New York $39.4M AUM 14.61% 1-Year Est. Return
HLC
Hunt Lane Capital New York $39.6M AUM 58.74% 1-Year Est. Return
KXA
KPCB XV Associates Menlo Park, California $35.8M AUM 57.59% 1-Year Est. Return

Foresite Capital Management III's Q3 2020 Portfolio in Review

As of Q3 2020, Foresite Capital Management III held 12 positions worth $134M, up 19% from $112M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Foresite Capital Management III's Q3 2020 filing shows 4 new, 3 increased and 2 closed positions. Its largest new stake was Verona Pharma: 1,111,112 shares worth $6.93M. The largest sale was Blueprint Medicines, an estimated $19.5M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 100% a quarter earlier.

  • Foresite Capital Management III's largest Q3 2020 buy was Verona Pharma: 1,111,112 shares worth $6.93M.
  • Foresite Capital Management III added most to Acceleron Pharma in Q3 2020, an estimated $6.63M increase.
  • Foresite Capital Management III fully exited Blueprint Medicines in Q3 2020, selling an estimated $19.5M.
  • Foresite Capital Management III's ten largest holdings make up 100% of its $134M portfolio in Q3 2020.
  • Foresite Capital Management III opened 4 new positions and closed 2 in Q3 2020.
  • Foresite Capital Management III's portfolio value rose 19% quarter-over-quarter to $134M.

Based on Foresite Capital Management III's 13F filing for Q3 2020, filed 13 Nov 2020.